Dhruv Life Sciences Pvt Ltd

Dhruv Life Sciences (DLS) is a bio-pharmaceutical company based in Hyderabad, the Biodiversity hub, and home of Genome Valley in India. The company specializes in discovering, re-engineering, manufacturing, and marketing injectable formulations with a profound impact on human healthcare. DLS started its commercial debut in 2013, offering a wide range of specialty and generic injectables in liquids, powders, lyophilized cakes, and pre-filled syringes. Within a short period, DLS has established itself as a reputed manufacturer of high-technology and unique biochemical injectables, catering to critical care segments including Cardio, Nephro, Neuro, and Gastro. The company holds 200+ licenses for over 80 formulations for both domestic and export markets and operates WHO GMP facilities in Hyderabad and Mumbai.

DLS products boast proven bio-equivalence of innovator drugs across global genetics, gaining recognition worldwide. With a dedicated sales force, DLS has increased market penetration, leading doctors to replace established brands with DLS products. Additionally, the company provides CMO/CDMO services to other pharmaceutical majors for their formulation R&D and manufacturing requirements, positioning itself as a trusted partner for several reputed multinational companies.

DLS is committed to ongoing R&D efforts to expand its product portfolio in super specialty drugs. The company focuses on developing products in biological Crude, API, and intermediates, highlighting its dedication to offering life-saving solutions. With its strong R&D team and a focus on continuous innovation, DLS is well-positioned to make a significant impact in the pharmaceutical industry.

Overall, Dhruv Life Sciences stands out as a promising player in the bio-pharmaceutical sector, with a robust product line, a focus on innovation, and a commitment to addressing critical healthcare needs. The company's success in penetrating the market and building a strong reputation makes it an attractive investment opportunity for venture capitalists seeking exposure to the pharmaceutical industry in India.